Johnson & Johnson (NYSE:JNJ) Given New $320.00 Price Target at UBS Group

Johnson & Johnson (NYSE:JNJ) had its price objective upped by research analysts at UBS Group from $280.00 to $320.00 in a note issued to investors on Wednesday, Benzinga reports. The firm currently has a “buy” rating on the stock. UBS Group’s price target would suggest a potential upside of 15.08% from the company’s current price.

Several other brokerages have also issued reports on JNJ. Johnson Rice restated a “buy” rating on shares of Johnson & Johnson in a research note on Monday, August 3rd. Scotiabank reiterated an “outperform” rating and set a $305.00 target price on shares of Johnson & Johnson in a research report on Thursday, July 16th. Argus set a $300.00 target price on shares of Johnson & Johnson in a research note on Wednesday, July 29th. TD Cowen lifted their price objective on shares of Johnson & Johnson from $250.00 to $300.00 and gave the company a “buy” rating in a research note on Monday, July 13th. Finally, Wall Street Zen cut Johnson & Johnson from a “buy” rating to a “hold” rating in a report on Saturday, August 1st. One analyst has rated the stock with a Strong Buy rating, eighteen have assigned a Buy rating and six have given a Hold rating to the company. According to data from MarketBeat, Johnson & Johnson currently has an average rating of “Moderate Buy” and an average target price of $272.83.

Johnson & Johnson Trading Up 2.5%

NYSE JNJ opened at $278.08 on Wednesday. The company has a current ratio of 1.09, a quick ratio of 0.81 and a debt-to-equity ratio of 0.44. The business has a fifty day simple moving average of $260.21 and a 200 day simple moving average of $244.39. Johnson & Johnson has a 12 month low of $173.33 and a 12 month high of $276.47. The firm has a market capitalization of $670.14 billion, a P/E ratio of 32.47, a PEG ratio of 2.54 and a beta of 0.24.

Johnson & Johnson (NYSE:JNJ) last posted its earnings results on Wednesday, July 15th. The company reported $2.90 earnings per share (EPS) for the quarter, topping the consensus estimate of $2.84 by $0.06. The firm had revenue of $25.31 billion during the quarter, compared to analyst estimates of $25.06 billion. Johnson & Johnson had a net margin of 21.48% and a return on equity of 32.42%. The business’s revenue was up 6.6% compared to the same quarter last year. During the same quarter in the prior year, the business posted $2.77 EPS. Johnson & Johnson has set its FY 2026 guidance at 11.600-11.750 EPS. On average, analysts predict that Johnson & Johnson will post 11.61 EPS for the current fiscal year.

Insider Buying and Selling at Johnson & Johnson

In other Johnson & Johnson news, EVP Jennifer L. Taubert sold 15,000 shares of the company’s stock in a transaction on Monday, August 17th. The stock was sold at an average price of $263.36, for a total value of $3,950,400.00. Following the transaction, the executive vice president owned 194,451 shares of the company’s stock, valued at $51,210,615.36. This represents a 7.16% decrease in their position. The sale was disclosed in a legal filing with the SEC, which is available through this hyperlink. Also, EVP Kathryn E. Wengel sold 10,000 shares of the company’s stock in a transaction that occurred on Thursday, June 11th. The stock was sold at an average price of $241.15, for a total transaction of $2,411,500.00. Following the completion of the sale, the executive vice president directly owned 114,288 shares of the company’s stock, valued at $27,560,551.20. The trade was a 8.05% decrease in their position. Additional details regarding this sale are available in the official SEC disclosure. Over the last quarter, insiders have sold 63,972 shares of company stock worth $16,245,605. 0.16% of the stock is owned by insiders.

Institutional Trading of Johnson & Johnson

Several institutional investors and hedge funds have recently bought and sold shares of the business. Outlook Capital Management LLC purchased a new position in Johnson & Johnson in the second quarter valued at $28,000. Blueline Advisors LLC acquired a new stake in shares of Johnson & Johnson in the 4th quarter worth $25,000. Cresta Advisors Ltd. acquired a new position in Johnson & Johnson in the 4th quarter valued at about $26,000. Bay Harbor Wealth Management LLC grew its stake in shares of Johnson & Johnson by 49.0% in the 4th quarter. Bay Harbor Wealth Management LLC now owns 149 shares of the company’s stock valued at $31,000 after buying an additional 49 shares during the period. Finally, Matrix Trust Co raised its position in shares of Johnson & Johnson by 56.2% during the 2nd quarter. Matrix Trust Co now owns 150 shares of the company’s stock valued at $38,000 after buying an additional 54 shares during the period. 69.55% of the stock is currently owned by institutional investors and hedge funds.

Key Johnson & Johnson News

Here are the key news stories impacting Johnson & Johnson this week:

• Positive Sentiment: Defensive rotation supported the shares. JNJ advanced while the broader market declined, suggesting investors favored its diversified healthcare portfolio and relatively low-volatility profile. Johnson & Johnson Rises As Market Takes a Dip: Key Facts
• Positive Sentiment: New products are offsetting lost sales. An analysis says Johnson & Johnson replaced approximately $913 million in lost sales with $2.4 billion in new sales, highlighting growth in newer products and the company’s ability to manage portfolio transitions. The key limitation is that less than half of the new sales translated into retained earnings, underscoring pressure on profitability. Johnson & Johnson Replaced Lost Sales With New Ones
• Positive Sentiment: The dividend remains a support for income investors. JNJ has extended its long record of annual dividend increases, reinforcing its appeal as a defensive healthcare holding, although investors remain attentive to future corporate changes that could affect growth or payout flexibility. Why Procter & Gamble’s Quieter Dividend Outpaces Johnson & Johnson’s Growth Story
• Neutral Sentiment: Third-quarter results are the next major catalyst. JNJ will discuss its third-quarter performance on an October 13 investor conference call, giving investors a closer look at product momentum, margins, litigation costs and updated full-year guidance. Johnson & Johnson to Host Investor Conference Call
• Negative Sentiment: Talc litigation remains an overhang. A recent talc verdict has renewed investor focus on JNJ’s potentially significant legal liabilities. Further adverse rulings or higher settlement costs could pressure earnings and valuation. Does Johnson & Johnson Talc Verdict Add to Its Legal Risk?
• Negative Sentiment: Analyst earnings expectations edged lower. Erste Group reduced its 2026 EPS forecast to $11.65 from $11.68. The revision is small and remains above consensus of roughly $11.61, but it signals limited near-term earnings upside at a valuation above historical defensive-stock norms.

About Johnson & Johnson

Johnson & Johnson is a multinational healthcare company headquartered in New Brunswick, New Jersey, that develops, manufactures and markets a broad range of products across pharmaceuticals, medical devices and previously consumer health. Founded in 1886 by the Johnson family, the company has grown into a global healthcare organization with operations and sales in many countries around the world.

The company’s pharmaceuticals business, organized largely under its Janssen research and development organization, focuses on prescription medicines across therapeutic areas such as immunology, infectious disease, oncology and neuroscience.